Osso VR partnered with Smith & Nephew to develop a VR training tool that will be showcased at this year's American Association of Orthopedic Surgeons' (AAOS) conference, taking place in Las Vegas from March 12-16. Orthopedic robotic systems continue to draw high interest from surgeons. The recent US FDA clearance of Zimmer Biomet's ROSA total knee replacement system will add competition to the current market dominated by Stryker's MAKO and Smith & Nephew's NAVIO.
Virtual training company [Osso VR] is kicking off this year's American Association of Orthopedic Surgeons' (AAOS) annual conference in Las Vegas by announcing a new partnership with Smith & Nephew PLC to develop a module to train surgeons on its NAVIO surgical system.
Smith & Nephew will showcase the new VR training module in the AAOS exhibit hall. More than 30,000 attendees are...
Ellipsis said it will use its new funding to expand its AI-powered voice assistant Sage across health systems. Ellipsis is part of the global vocal biomarker market, which is expected to exceed $9bn by the end of 2033, according to a research market report.
After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.
European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.
European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.
Preparations for the reauthorization of the Medical Device User Fee Amendments for 2028-2032 are underway, with the US FDA announcing a public meeting for 4 August. After negotiations with industry and other stakeholders, a draft agreement is due to Congress by 15 January 2025.
